MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

78.7 -10.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.39

Max

81.68

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+50.98% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.9B

12B

Ankstesnė atidarymo kaina

88.75

Ankstesnė uždarymo kaina

78.7

Naujienos nuotaikos

By Acuity

50%

50%

185 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 17:04; UTC

Pagrindinės rinkos jėgos

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026-04-11 00:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Big Yachts, Big Bucks -- Barrons.com

2026-04-10 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026-04-10 21:01; UTC

Uždarbis

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026-04-10 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 20:31; UTC

Rinkos pokalbiai

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 19:15; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-10 19:15; UTC

Rinkos pokalbiai

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026-04-10 18:38; UTC

Rinkos pokalbiai

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026-04-10 18:25; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Precious Metals Finish With Weekly Gains -- Market Talk

2026-04-10 18:05; UTC

Rinkos pokalbiai

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026-04-10 17:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026-04-10 17:26; UTC

Uždarbis

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026-04-10 17:10; UTC

Rinkos pokalbiai

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026-04-10 17:00; UTC

Svarbiausios naujienos

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026-04-10 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-10 16:12; UTC

Uždarbis

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026-04-10 16:11; UTC

Uždarbis

Partners Group: Traditional Programs Contributed $3.3B

2026-04-10 16:10; UTC

Uždarbis

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026-04-10 16:10; UTC

Uždarbis

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026-04-10 16:10; UTC

Uždarbis

Partners Group 1Q New Client Demand $8.3B

2026-04-10 16:09; UTC

Uždarbis

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026-04-10 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Plenitude Completes Acquisition of Acea Energia

2026-04-10 15:38; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

50.98% į viršų

12 mėnesių prognozė

Vidutinis 131.61 USD  50.98%

Aukščiausias 175 USD

Žemiausias 90 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

185 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat